Neuroendocrinology News

In patients with hypercortisolism and difficult-to-control type 2 diabetes, mifepristone lowered HbA1c at 24 weeks compared with placebo, researchers reported at World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.

Neurocrine Biosciences announced that the FDA has approved crinecerfont as an adjunct to glucocorticoid replacement to control androgens for patients with congenital adrenal hyperplasia.

A machine learning model was more accurate than 12 experienced endocrinologists in identifying adults with acromegaly based on voice recordings, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

A generic version of a treatment for acromegaly is now available for adults in the U.S., according to an industry press release.

Adults diagnosed with endogenous Cushing’s syndrome have a higher risk for developing cancer compared with controls without the condition, according to data published in the European Journal of Endocrinology.

Some types of endocrine-disrupting chemicals may act as kisspeptin or gonadotropin-releasing hormone receptor agonists and could induce early puberty for children, according to in vitro findings published in Endocrinology.

Having high insulin-like growth factor I levels over a longer duration increased risk for cancer among adults with acromegaly, but not for those with nonfunction pituitary adenoma, according to study data.

The FDA has granted priority review designation for two new drug applications for a selective corticotropin-releasing factor type 1 receptor to treat congenital adrenal hyperplasia, according to a press release.

ORLANDO — Nearly one-quarter of adults with difficult-to-control type 2 diabetes also have hypercortisolism, and treating hypercortisolism may also benefit glycemic control in those with both conditions, according to speakers.